Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00078349" target="_blank" >RIV/65269705:_____/23:00078349 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/23:10471795

Výsledek na webu

<a href="https://www.nature.com/articles/s41375-023-02008-6" target="_blank" >https://www.nature.com/articles/s41375-023-02008-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-023-02008-6" target="_blank" >10.1038/s41375-023-02008-6</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

Popis výsledku v původním jazyce

Patients with polycythemia vera (PV), an incurable Philadelphia-negative myeloproliferative neoplasm, have shortened survival due to thrombohemorrhagic complications and evolution to myelofibrosis or acute myeloid leukemia [1, 2]. Clinical management of PV has primarily addressed the thrombotic risk, whereas prevention of disease progression remains a significant unmet need [3]. Interferon alfa is recognized as a disease-modifying treatment for PV that may reduce the risk of myelofibrotic progression and potentially prolong overall survival according to retrospective data, but prospective studies to confirm these findings have been lacking [4]. Final results from the large PROUD-PV trial and its extension CONTINUATION-PV are now available comparing ropeginterferon alfa-2b (BESREMi(R)) with hydroxyurea or best available treatment (BAT) over a total of 6 years.

Název v anglickém jazyce

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

Popis výsledku anglicky

Patients with polycythemia vera (PV), an incurable Philadelphia-negative myeloproliferative neoplasm, have shortened survival due to thrombohemorrhagic complications and evolution to myelofibrosis or acute myeloid leukemia [1, 2]. Clinical management of PV has primarily addressed the thrombotic risk, whereas prevention of disease progression remains a significant unmet need [3]. Interferon alfa is recognized as a disease-modifying treatment for PV that may reduce the risk of myelofibrotic progression and potentially prolong overall survival according to retrospective data, but prospective studies to confirm these findings have been lacking [4]. Final results from the large PROUD-PV trial and its extension CONTINUATION-PV are now available comparing ropeginterferon alfa-2b (BESREMi(R)) with hydroxyurea or best available treatment (BAT) over a total of 6 years.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

1476-5551

Svazek periodika

37

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

4

Strana od-do

2129-2132

Kód UT WoS článku

001063663500003

EID výsledku v databázi Scopus

2-s2.0-85168859320